Champions Oncology, Inc. (NASDAQ:CSBR) Q3 2025 Earnings Call Transcript
Operator: Greetings. Welcome to the Champions Oncology Third Quarter Fiscal Year 2025 Earnings Call [Operator Instructions]. Please note, this conference is being recorded.
Champions Oncology Inc. (CSBR)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 138,839 | $1,189,850 | +16% | 0% |
| 2. | Millennium Management Israel Englander | 10,941 | $93,764 | +2% | 0% |
| 3. | Citadel Investment Group Ken Griffin | 10,868 | $93,139 | 0% | |
| 4. | 6,500 | $55,705 | 0% | ||
| 5. | 1,000 | $8,570 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.50 | 1,000 | Director | 198,625 | 2024-01-12 | Filing | |
| $6.27 | 2,000 | Director | 197,625 | 2024-01-11 | Filing | |
| $6.31 | 2,944 | Director | 195,625 | 2024-01-10 | Filing | |
| $6.25 | 3,000 | Director | 192,681 | 2024-01-09 | Filing | |
| $6.15 | 1,000 | Director | 189,681 | 2024-01-08 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $11.35 | 31,443 | Director | 0 | 2020-12-16 | Filing | |
| $5.25 | 75 | Officer, Director | 837,168 | 2020-03-24 | Filing | |
| $6.99 | 708,155 | Large Shareholder | 1,713,720 | 2020-03-06 | Filing | |
| $13.75 | 5,000 | Director | 57,500 | 2018-11-06 | Filing | |
| $13.02 | 8,333 | Director | 62,500 | 2018-09-20 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,421,673 | $20,753,738 | 2.65% | |
| 2. | 1,713,720 | $14,686,580 | 0.82% | |
| 3. | 608,915 | $5,218,402 | 0.08% | |
| 4. | 307,002 | $2,631,007 | 0% | |
| 5. | 116,300 | $996,691 | 0% |
News See All
Champions Oncology, Inc. (NASDAQ:CSBR) Q2 2025 Earnings Call Transcript
Operator: Greetings. Welcome to the Champions Oncology Second Quarter Fiscal Year 2025 Earnings Call. At this time, all participants are in a listen only mode.
Champions Oncology, Inc. (NASDAQ:CSBR) Q1 2025 Earnings Call Transcript
Operator: Greetings. Welcome to the Champions Oncology First Quarter Fiscal Year 2025 Earnings Call. At this time, all participants are in a listen-only mode.
Champions Oncology, Inc. (NASDAQ:CSBR) Q4 2024 Earnings Call Transcript
Operator: Greetings. Welcome to Champions Oncology's Fourth Quarter Fiscal Year 2024 Earnings Conference Call. At this time, all participants have been placed on a listen-only mode.
Champions Oncology, Inc. (NASDAQ:CSBR) Q3 2024 Earnings Call Transcript
Operator: Greetings. Welcome to the Champions Oncology Third Quarter Fiscal Year 2024 Earnings Call. At this time all participants are in a listen-only mode.
Champions Oncology, Inc. (NASDAQ:CSBR) Q2 2024 Earnings Call Transcript
Operator: Greetings. Welcome to the Champions Oncology Second Quarter Fiscal Year 2024 Earnings Call. At this time, all participants are in a listen-only mode.
Champions Oncology, Inc. (NASDAQ:CSBR) Q1 2024 Earnings Call Transcript
Operator: Greetings. Welcome to the Champions Oncology First Quarter Fiscal Year 2024 Earnings Call. At this time all participants are in a listen-only mode.
Champions Oncology, Inc. (NASDAQ:CSBR) Q4 2023 Earnings Call Transcript
Operator: Greetings, and welcome to Champions Oncology's Fourth Quarter and Fiscal Year-End 2023 Earnings Conference Call. At this time, all participants are in listen-only mode.
Champions Oncology, Inc. (NASDAQ:CSBR) Q3 2023 Earnings Call Transcript
Operator: Good day, everyone, and welcome to the Champions Oncology Third Quarter Fiscal Year 2023 Earnings Call. It is now my pleasure to turn the floor over to your host, Dr.
Champions Oncology, Inc. (NASDAQ:CSBR) Q2 2023 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and welcome to the Champions Oncology Second Quarter Fiscal Year 2023 Earnings Call.